Biologics Market: Region-wise Outlook
Biologics Market
Biologics Market: Global Industry Analysis and Opportunity Assessment 2016-2026
- Ongoing
- March 2020
- REP-GB-1249
-
This Biologics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Biologics market.
Biologics are drugs in the form of genetically engineered proteins, derived from human genes. As per the US FDA, biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. The biologic drugs are derived from a variety of natural sources such as humans, animals, or microorganisms and consist of products, such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Advanced biotechnology techniques and complex processes are used to manufacture biologics. They are at the forefront of biomedical research.
Biologics Market: Drivers and Restraints
Market Growth Analysis
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Need granular data and specific insights that are hard to get?
Drivers for the biologics market include big brand name drugs losing patent extensions, growing incidence of chronic diseases and their diagnoses across the globe, increased availability of advanced diagnostics, rising government initiatives in healthcare and growing technological advancements in research and development across the globe by big drug makers to sustain competition and invest in incremental innovation. Other factors increasing the demand for biologic drugs include rising regulatory convergence and better access to healthcare for all nations.
Restraints for the market include difficulty in manufacturing, as the drugs are highly complex in nature. They must be processed under tightly controlled conditions/controls, maintained throughout the production process. This type of atmosphere and quality control procedures are not easily available in less developed nations. Environmental contamination needs to be eliminated from the manufacturing process. Further, biologics are extremely susceptible to light, heat conditions, and need extremely good refrigeration processes, which is not available uniformly throughout the world.
Biologics Market: Segmentation
Biologics Market: Overview
Depending on geographic regions, biologic drug market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
Biologics Market: Key Players
Some of the key players in biologics market are Unilife Corporation, Retractable Technologies, Inc., Smiths Medicals, Becton, Dickinson & Company, Smiths Medical, Terumo Corporation, Pfizer Inc. (AC. Hospira), Roche Diagnostics, AstraZeneca, Bayer AG, Genzyme, GSK Biologicals, Lundbeck, Novartis AG, and Merck KGaA.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as, geographies, product class and sub-class, and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.
Unique Requirements? Customize this Report
- Customize by Region, Country, Application, Product, & other segments
- Integrate our Insights with your Existing Data
- Determine the scope of the study to suit your requirements
Let FMI Help You!
- Gain Insights on Key Biologics Market Impacting Forces
- Know the Winning Strategies of Market Leaders
- Get Deep-Dive Analysis on Each Segment
- Identify the Sources that will Drive Top-Line Revenue
Biologics Market can be segmented into these following ways:
- Segmentation by product type
- Vaccines
- Blood and Blood Products
- Allergenic extracts
- Human Cells and Tissues
- Proteins
- Gene Therapies
- Cellular Therapies
- Xenotransplantation Products
- Segmentation by application
- Rheumatoid arthritis
- Anemia
- Cancer
- Diabetes
- Others
- Segmentation by source material
- Humans
- Avian Cell Culture
- Yeast
- Bacteria
- Insects Cell Culture
- Transgenics
Biologics market is at risk over the forthcoming years due to leading biologic drugs expected to lose exclusivity over the next seven years. The patented biologic drugs are expected to be replaced by biosimilar drugs. Competition is expected to be limited in the market as the drugs are expected to be formed using various types of innovative technologies. Increasing geriatric population, early onset of ageing, increasing awareness for technologically advanced medical procedures and drugs, higher spending power, and rising incidence of chronic diseases such as cancer, rheumatoid arthritis, etc. are expected to drive the market growth of biologic drugs.
Biologics Market: Region-wise Outlook
In terms of geography, North America and Europe dominate the market, followed by Asia-Pacific. However, rising technological advancement in healthcare and systematic drug review process will drive the markets over North America, Japan and other regions. Europe currently dominates the biosimilars market driven by technically advanced healthcare infrastructure and high patient awareness & regulatory harmonization. Increasing funding for development of biologics available through public-private partnerships, availability of high-quality research infrastructure and innovative strategies developed by drug makers to restrict entry of new players are factors expected to contribute to market growth of biologics over the forecast period. Emerging markets include Eastern European countries followed by countries in Eastern Africa. Rising disease incidences in these countries is expected to prove favorable for the growth of the biologics market.
Biologics Market: Key Players
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Russia, Poland)
- Asia Pacific (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa, N. Africa)
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
